Plasma TIMP-1 in patients with metastatic colorectal cancer treated with first-line oxaliplatin-based therapy with or without cetuximab: Results from the Nordic VII study.
Line Schmidt Tarpgaard
No relevant relationships to disclose
Tormod Kyrre Guren
No relevant relationships to disclose
Bengt Glimelius
Research Funding - Merck Serono
Halfdan Sorbye
Consultant or Advisory Role - Merck Serono (U)
Research Funding - Merck Serono
Tone Ikdahl
No relevant relationships to disclose
Ib Jarle Christensen
No relevant relationships to disclose
Camilla Qvortrup
No relevant relationships to disclose
Elin Kure
No relevant relationships to disclose
Per Pfeifer
Consultant or Advisory Role - Merck Serono (U)
Research Funding - Merck Serono
Hans J. Nielsen
No relevant relationships to disclose
Nils BrĂ¼nner
No relevant relationships to disclose